Despite the availability of once-daily oral emtricitabine–tenofovir disoproxil fumarate (F/TDF) as a highly effective pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) prevention, significant unmet needs remain.1,2 Many individuals, particularly adolescent girls and young women,

Tirzepatide is a once-weekly GIP and GLP-1 receptor agonist with a once-weekly dosing regimen that has previously been FDA-approved for treating type 2 diabetes mellitus (T2DM). Its effectiveness in reducing body weight in obese T2D patients has been demonstrated in the SURMOUNT-1 trial. However, it

In the 2022 Conference on Retroviruses and Opportunistic Infections (CROI), Dr. Susan Eshleman from the School of Medicine of John Hopkins University, Baltimore of the United States (US), presented a study on human immunodeficiency virus (HIV) screening using ribonucleic acid (RNA) assays in patient

Thirty months following treatment interruption, a patient known as the "London patient" has continued to remain in sustained remission of human immunodeficiency virus (HIV) status.¹

Advances in the HIV prevention and treatment have increased the likelihood of eliminating the HIV epidemic, although changes in the disease management guidelines have yet to be implemented. Indeed, the HIV experts always emphasize the importance of accessible HIV testing campaigns,

The estimated number of people living with human immunodeficiency virus (HIV) infection was 36.9 million in 2014.¹ An estimated 15.2% of people living with HIV are located in the Asia-Pacific region.²